GSK lung cancer drug shows 61% response rate in early global trial

Data ReadoutpositivePositive

AI Analysis

Summary

GSK reported a 61% response rate for a lung cancer drug in an early global trial. The article text provided contains only the headline, so drug name, trial phase and patient numbers are not specified.

Clinical Trial Data

Phase

Phase_1

Outcome Details

61% response rate reported in an early global trial of a GSK lung cancer drug

Importance:5/10

Sentiment:

0.60

oncologylung cancerearly-stage trialresponse rateclinical data

Related Companies

$GSK

Read the original article

Published by yahoo_finance on October 19, 2026 6:19 AM

Read Original